Table 3.
Univariate and multivariate analysis of factors associated with overall survival
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p-value | Hazard ratio | 95% CI | p-value | |
| Age | 0.991 | 0.969–1.014 | 0.46 | |||
| Gender male (vs. female) | 1.033 | 0.526–2.028 | 0.93 | |||
| ECOG-PS 1 (vs. PS 0) | 2.067 | 1.172–3.648 | 0.01 | 1.310 | 0.697–2.462 | 0.40 |
| Child-Pugh B (vs. A) | 1.019 | 0.533–1.949 | 0.95 | |||
| HCV (vs. HBV) | 1.492 | 0.768–2.897 | 0.24 | |||
| NonBNonC (vs. HBV) | 1.300 | 0.651–2.597 | 0.46 | |||
| Macrovascular invasion | 1.622 | 0.994–2.646 | 0.05 | |||
| Extrahepatic metastasis | 1.432 | 0.874–2.348 | 0.15 | |||
| BCLC stage C (vs. stage B) | 1.757 | 1.068–2.891 | 0.03 | 1.573 | 0.915–2.705 | 0.10 |
| AFP ≥ 400 ng/ml (vs. < 400 ng/ml) | 2.332 | 1.407–3.862 | 0.001 | 2.221 | 1.338–3.685 | 0.002 |
| Combination therapy | 0.494 | 0.282–0.866 | 0.01 | 0.521 | 0.297–0.915 | 0.02 |
95% CI – 95% confidence interval; ECOG-PS – Eastern Cooperative Oncology Group performance status; BCLC stage – Barcelona Clinic Liver Cancer stage; AFP – α-fetoprotein